VRDN Q3 2023 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72,000-94.0% YoY

Gross Profit

$72,000100.0% margin

Operating Income

-$51M-71144.4% margin

Net Income

-$48M-66194.4% margin

EPS (Diluted)

$-1.09

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$39M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$329M

Total Liabilities

$45M

Stockholders' Equity

$284M

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72,000	$1M	-94.0%
Gross Profit	$72,000	-$21M	+100.3%
Operating Income	-$51M	-$30M	-72.0%
Net Income	-$48M	-$29M	-64.9%

Revenue Segments

Collaboration Revenue

$100,000100%